CytomX Therapeutics, Inc. (NASDAQ:CTMX) CFO Debanjan Ray sold 2,500 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $20.00, for a total transaction of $50,000.00. Following the completion of the sale, the chief financial officer now directly owns 12,126 shares in the company, valued at $242,520. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Debanjan Ray also recently made the following trade(s):

  • On Monday, October 2nd, Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock. The shares were sold at an average price of $18.10, for a total transaction of $45,250.00.
  • On Friday, September 1st, Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock. The shares were sold at an average price of $17.17, for a total transaction of $42,925.00.
  • On Wednesday, August 9th, Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock. The shares were sold at an average price of $15.00, for a total transaction of $37,500.00.

CytomX Therapeutics, Inc. (CTMX) traded up $0.31 during mid-day trading on Friday, hitting $20.23. 278,865 shares of the stock traded hands, compared to its average volume of 311,488.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.30). CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. The firm had revenue of $8.75 million for the quarter, compared to analysts’ expectations of $4.95 million. analysts anticipate that CytomX Therapeutics, Inc. will post -1.46 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/11/03/insider-selling-cytomx-therapeutics-inc-ctmx-cfo-sells-2500-shares-of-stock.html.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc raised its position in shares of CytomX Therapeutics by 28.6% during the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 1,434 shares during the last quarter. First Quadrant L P CA acquired a new position in shares of CytomX Therapeutics during the 2nd quarter worth about $160,000. Goldman Sachs Group Inc. acquired a new position in shares of CytomX Therapeutics during the 1st quarter worth about $190,000. Cubist Systematic Strategies LLC acquired a new position in shares of CytomX Therapeutics during the 2nd quarter worth about $174,000. Finally, American International Group Inc. raised its position in shares of CytomX Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 12,580 shares of the biotechnology company’s stock worth $217,000 after purchasing an additional 834 shares during the last quarter. Hedge funds and other institutional investors own 60.02% of the company’s stock.

Several equities research analysts have commented on CTMX shares. Bank of America Corporation upped their price target on shares of CytomX Therapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, October 4th. Nomura upped their price target on shares of CytomX Therapeutics to $44.00 and gave the company a “buy” rating in a report on Wednesday, October 4th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of CytomX Therapeutics in a report on Wednesday, October 4th. BidaskClub raised shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 8th. Finally, Zacks Investment Research raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a report on Monday, October 16th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the stock. CytomX Therapeutics has a consensus rating of “Hold” and a consensus price target of $31.88.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.